MCET (MultiCell Technologies) Short Percentage of Float

View and export this data going back to . Start your Free Trial

What is MultiCell Technologies Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of MultiCell Technologies's Short Percentage of Float

For the Biotechnology subindustry, MultiCell Technologies's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MultiCell Technologies's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's Short Percentage of Float falls into.

MultiCell Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MultiCell Technologies Inc (OTCPK:MCET) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

N/A

Address

4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204

Website

http://www.multicelltech.com

MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.

Executives

Stephen Chang	director	12912 CAMINO DEL VALLE, POWAY CA 92064
Anthony E Altig	director	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, JERSEY CITY NJ 07302
Gregory F Szabo	director, officer: President and Treasurer	14505 N. HAYDEN ROAD, #305, SCOTTSDALE AZ 85260

MultiCell Technologies Headlines

No Headlines